^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GST-HG16

    i
    Other names: GST-HG16, GST HG 161
    Company:
    Fujian Cosunter, WuXi AppTec
    Drug class:
    c-MET inhibitor
    Related drugs:
    4years
    [VIRTUAL] First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor. (ASCO 2020)
    GST-HG161 has been well tolerated to date in study patients with a manageable safety profile. The dose escalation is expected to continue to the proposed 7th cohort at 900 mg. Research Funding: Cosunter Co., Ltd,
    Clinical • P1 data
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET expression
    |
    GST-HG16